Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + albumin-bound paclitaxel + lenvatinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of QL1706 (iparomlimab and tuvonralimab), albumin-bound paclitaxel, and lenvatinib. QL1706, developed by Qilu Pharmaceutical using the MabPair platform, is a bifunctional antibody product that simultaneously targets the PD-1 and CTLA-4 immune checkpoints to enhance anti-tumor T-cell activity. Albumin-bound paclitaxel (nab-paclitaxel) is a nanoparticle formulation of the chemotherapy agent paclitaxel that inhibits microtubule dynamics, leading to cell cycle arrest. Lenvatinib is an oral multi-target tyrosine kinase inhibitor that blocks VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, thereby inhibiting angiogenesis and tumor cell proliferation. This triplet regimen is being investigated by Sun Yat-sen University as a second-line treatment for patients with unresectable or metastatic biliary tract cancer, particularly those who have progressed on prior immunotherapy and chemotherapy.
- Brand names
- Iparomlimab and TuvonralimabAbraxane
- Other names
- nab-paclitaxelQL-1706QL1706QL 1706
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on QL1706 + albumin-bound paclitaxel + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + albumin-bound paclitaxel + lenvatinib.